San Rafael, California – BioMarin has announced the acquisition of Amicus Therapeutics (https://amicusrx.com/). According to the company announcement BioMarin Pharmaceutical Inc. is a prominent global biotechnology company, established in 1997 and headquartered in San Rafael, California, dedicated to developing and delivering medicines for individuals with genetically defined rare diseases. The company boasts a strong track record of innovation, evidenced by its eight commercial therapies and a robust clinical and preclinical pipeline. BioMarin employs a distinctive approach to drug discovery and development, aiming to harness the full potential of genetic science to create category-defining medicines that significantly improve patients’ lives. Through its recent acquisition of Amicus Therapeutics for $4.8 billion, BioMarin is expanding its leadership in rare diseases, specifically adding treatments for lysosomal storage disorders. This strategic move is expected to immediately accelerate BioMarin’s revenue growth and strengthen its financial outlook, incorporating high-growth products like Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease into its commercial portfolio.

To learn more about BioMarin, visit https://www.biomarin.com/
Company LinkedIn Page: https://www.linkedin.com/company/biomarin/

Company Contact:

BioMarin
770 Lindaro Street
San Rafael, CA 94901
415-505-6700

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.